Trial Profile
Clinical Research of radiotherapy combined with apatinib mesylate tablets in the treatment of residual, recurrent and metastatic sarcoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- 20 Nov 2017 New trial record